Transarterial Chemoembolization (TACE) is a minimally invasive treatment for liver cancer that involves injecting chemotherapy drugs directly into the tumor’s blood supply, followed by the insertion of tiny particles to block the blood flow to the tumor.
The procedure is typically performed under local anesthesia and with the guidance of imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI). The interventional radiologist inserts a catheter through a small incision in the patient’s groin and guides it to the artery supplying blood to the liver tumor. The chemotherapy drug is then injected directly into the artery leading to the tumor. After the chemotherapy injection, the radiologist injects tiny particles called embolic agents that block the blood flow to the tumor, leading to its death.
The goal of TACE is to deliver high concentrations of chemotherapy drugs to the tumor while minimizing their spread to other parts of the body. By blocking the blood flow to the tumor, TACE also starves the tumor of oxygen and nutrients, causing it to shrink or stop growing.
๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ญ: https://www.alliedmarketresearch.com/request-toc-and-sample/13781
TACE is typically used to treat liver cancers that have not spread to other parts of the body and are too large to be treated with surgery. It is also used in cases where surgery is not an option due to the patient’s health condition. TACE can be used alone or in combination with other treatments such as surgery, radiation therapy, or immunotherapy.
Like any medical procedure, TACE carries some risks, including bleeding, infection, and damage to healthy liver tissue. However, TACE is generally considered a safe and effective treatment for liver cancer, and it has been shown to prolong the survival of patients with this disease.
Top Impacting Factors
- Increase in cases of hepatocellular carcinoma (HCC), constant growth of drug consumption, and the development of cardiovascular diseases, and rise in demand for advanced cancer treatment and procedures are factors that drive the growth of the transarterial chemoembolization market.
- In addition, increase in healthcare expenditure; availability of skilled professionals, and rise in R&D activities to develop and launch novel therapies in the market; are some factors, which boost the market growth for transarterial chemoembolization.
- However, higher cost of treatment and complications associated with embolization may hinder the market growth.
- Contrarily, favorable reimbursement policies and support from the government for regulatory approval present new pathways in the industry.
The choice of which liver segments to treat with transarterial chemoembolization (TACE) depends on the location and extent of the liver cancer. TACE is typically used to treat liver tumors that are too large or too numerous to be treated with surgery, and are usually located in one or more specific segments of the liver.
The liver is divided into eight segments, each of which has its own blood supply. During TACE, the interventional radiologist inserts a catheter into the artery that supplies blood to the liver segments where the tumor is located. The chemotherapy drug is then injected directly into this artery, followed by embolic agents that block the blood flow to the tumor.
The specific liver segments treated during TACE depend on the location and extent of the tumor. In some cases, TACE may be performed on multiple liver segments to treat tumors that have spread throughout the liver. The interventional radiologist will use imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) to guide the catheter to the appropriate liver segments and ensure that the chemotherapy and embolic agents are delivered precisely to the targeted area.
Key Benefits of the Report
- This study presents the analytical depiction of the transarterial chemoembolization industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the transarterial chemoembolization market share.
- The current market is quantitatively analyzed to highlight the transarterial chemoembolization market growth scenario.
- Porterโs five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed transarterial chemoembolization market analysis based on competitive intensity and how the competition will take shape in coming years
๐๐ ๐๐๐๐๐ซ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ, ๐๐ฅ๐ข๐๐ค: https://www.alliedmarketresearch.com/request-for-customization/13781
๐๐๐จ๐ฎ๐ญ ๐๐ฌ:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.